The 2025 EQUAL <i>Pneumocystis</i> Score—an ECMM tool to measure QUALity in <i>Pneumocystis</i> pneumonia management
The 2025 EQUAL <i>Pneumocystis</i> Score offers a concise, evidence-based tool for the optimal management of PCP. This can be useful in daily practice for a quick overview and may be used to measure guideline adherence in research settings. It has not yet been assessed whether higher EQUAL <i>Pneumocystis</i> Scores are associated with improved patient outcomes.
Authors
- Jan Grothe (ORCID: https://orcid.org/0000-0001-8498-231X)
- Jean‐Pierre Gangneux (ORCID: https://orcid.org/0000-0002-4974-5607)
- Florence Robert-Gangneux (ORCID: https://orcid.org/0000-0003-4493-596X)
- Rosanne Sprute (ORCID: https://orcid.org/0000-0003-2457-6437)
- Philipp Koehler (ORCID: https://orcid.org/0000-0002-7386-7495)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Jacques F. G. M. Meis (ORCID: https://orcid.org/0000-0003-3253-6080)
- Luise Hänsel (ORCID: https://orcid.org/0000-0002-4494-5159)
Institutions
- Inserm (FR)
- University of Cologne (DE)
- Institut de Recherche en Santé, Environnement et Travail (FR)
- Canisius-Wilhelmina Ziekenhuis (NL)
- German Center for Infection Research (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- Université de Rennes (FR)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1093/jacamr/dlaf165
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Medpace
- Deutsches Zentrum für Infektionsforschung
- HELIOS Kliniken
- Cidara Therapeutics
- Jazz Pharmaceuticals
- Moderna
- Deutsche Forschungsgemeinschaft
- European Society of Clinical Microbiology and Infectious Diseases
- Bundesministerium für Bildung und Forschung
- Astellas Pharma
- Shionogi
- Ludwig-Maximilians-Universität München
- Ipsen
- Seqirus
- Sanofi-Aventis Deutschland